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Amrita KrishnanINTRODUCTION
High-dose chemotherapy and autologous stem cell
transplantation (SCT) or allogeneic SCT can lead to
durable remissions in patients with hematologicmalig-
nancies. In the mid-1980s the first studies demonstrat-
ing the use of peripheral blood stem cells (PBSC) for
autologous transplantation instead of bone marrow
(BM) were performed. Subsequently, PBSC have
largely supplanted BM, and are, in part, the reason
for the decline in procedural related toxicity of autolo-
gous SCT [1]. In the allogeneic setting, the use of
reduced-intensity conditioning (RIC), and better
graft-versus-host disease (GVHD) prophylaxis has
reduced treatment-related mortality (TRM). Initial
transplant studies were limited to younger patients
and those without significant infections such as HIV.
However, there have been advances in HIV care. For
example, the advent of protease inhibitor-based highly
active antiretroviral therapy (HAART) and improved
infection prophylaxis have greatly improved survival
in HIV-infected patients. This has led to the paradigm
of HIV as a ‘‘chronic condition’’ akin to diabetes that
should not preclude autologous transplant. Further-
more, now that the toxicity of autologous and alloge-
neic transplant decreased, transplant is feasible in
older patients, and, therefore, arbitrary age cutoffs
may exclude patients from a potentially curative proce-
dure. Other methods of risk stratification such as the
comorbidity index can provide a more accurate assess-
ment of transplant-related risk and help in the deter-
mination of appropriate conditioning regimens.
Herein we review the data on SCT in these ‘‘vulnera-
ble’’ patients, that is, those with HIV infection and
elderly patients, and we will also discuss the use of
the comorbidity index and how it can aid in the
decision-making process for patients by optimizingivision ofHematology/HCT,City ofHopeComprehen-
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Malignancies are now the leading cause of mortal-
ity in HIV-infected individuals. Both Hodgkin (HL)
and non-Hodgkin lymphoma (NHL) are increased in
incidence in HIV-positive patients [2]. Pre-HAART,
even the use of conventional dose chemotherapy
for the treatment of AIDS-related lymphoma was dif-
ficult because of its significant myelosuppression and
infection risk. This led to the early paradigm of less
intensive therapy for HIV-associated lymphoma [3].
However, with the widespread use of HAART, HIV
patients have improved hematologic reserve and infre-
quent opportunistic infections. Hence, standard regi-
mens in HIV-negative lymphomas such as CHOP
and ABVD are now commonly used in AIDS lym-
phoma, and may lead to high remission rates [4].Autologous Transplantation in HIV Lymphoma
Autologous SCT has been proved in randomized
trials to be superior to conventional dose salvage ther-
apy for NHL in HIV-negative patients with relapsed
lymphoma [5]. Long-term remissions were also re-
ported with this approach in HIV-negative relapsed
or refractory HL [6]. HIV-positive patients were ex-
cluded from these trials because of their poor hemato-
logic reserve, and even more significantly, the high risk
of overwhelming infection after myeloablative therapy
in an already immunocompromised host. However, in
themid-1990s, the era ofHAART, select centers in the
United States and Europe undertook pilot studies of
autologous transplant in patients with AIDS lym-
phoma. The initial series of 14 patients from France
included both NHL and HL [7]. They utilized both
chemotherapy-based and radiation-based condition-
ing regimens. All the patients engrafted. However, de-
spite the continued use of HAART in 13 of the 14
patients, opportunistic infections (OIs) did occur.
Eight patients died: 6 from lymphoma, 1 from AIDS,
and 1 from a secondary malignancy. This pilot study
demonstrated the feasibility of the procedure and set
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earlier in the course of treatment for AIDS lymphoma.
A similar study was initiated at the City of Hope
Medical Center in 1997, and recently updated to in-
clude long-term follow-up on 32 patients [8]. All pa-
tients were on HAART at study entry and had to
have a median HIV viral load of\10,000 genome cop-
ies/mL. The patients received either chemotherapy-
based conditioning with CBV (cyclophosphamide
[Cy], carmustine, etoposide) or a total body irradiation
(TBI)-based regimen of 1200 cGy TBI plus Cy and
etoposide. Themedian time to neutrophil engraftment
was 10 days. Of note, delayed engraftment was seen in
1 patient on zidovudine (AZI). This led to an update in
clinical practice to exclude AZT-based regimens. Sim-
ilar to the French series, OIs were seen and included
cytomegalovirus (CMV) viremia retinitis in 1 patient,
PCP pneumonia in 2 patients not compliant with pro-
phylaxis, and varicella zoster virus (VZV) in 2 patients
not on prophylaxis. Subsequently, zoster prophylaxis
for 1 year posttransplant has been instituted. In addi-
tion, routine monitoring for CMV reactivation is rec-
ommended for at least 100 days posttransplant. There
was 1 transplant-related death in the oldest patient,
aged 68 years, at day 122 because of multiorgan fail-
ure. Late complications included secondary myelodys-
plastic syndromes (MDS) in 1 patient. This patient
ultimately died of MDS while in remission from his
lymphoma. Median follow-up for the group is 47
months, 2-year progression-free survival (PFS) and
overall survival (OS) are 80% and 81%, respectively
(Figure 1).
The AIDSmalignancy consortium opened amulti-
institutional study of autologous SCT using high dose
busulfan (Bu) and Cy conditioning based on prior
experiences with this regimen in older patients with
HIV-negative NHL and HL [9]. Twenty-seven pa-
tients were enrolled on the study, and 20 ultimatelyOverall Survival
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Figure 1. Overall survival of patients.went to transplant. All patients were on HAART, but
zidovudine was excluded because of its potential for
myelosuppression, and ritonavir because of its p450
effects on drug metabolism. An HIV viral load of
\110,000 copies/mL was required for eligibility.
Median time to white cell engraftment was 11 days.
One patient died at day133 of hepatic veno-occlusive
disease and multiorgan failure. Ten patients were alive
and event free at a median of 23 weeks post transplant.
Event-free survival (EFS) and OS probabilities at 6
months posttransplantation were 49.5% and 74.4%,
respectively [9].
The largest series of autologous transplant was
from the European Blood and Marrow Transplant
(EBMT), and included 4 patients, 10 HL, and 34
NHL. Of note, patients with induction failure and
chemotherapy-resistant relapse were eligible. Despite
the inclusion of this high-risk population, disease-
free survival (DFS) was 55% at the median follow-up
of 36 months [10]. The EBMT also performed a retro-
spective case controlled analysis of 40 HIV-positive
and 46 HIV-negative patients undergoing autologous
transplant for lymphoma. Patients were matched for
age and disease status at transplant stage at diagnosis.
OS/PFS were not statistically different between the
groups [11].
In summary, these trials demonstrate that select
patients with HIV infection can benefit from autolo-
gous transplant. Differences in long-term DFS likely
reflect patient selection with some centers including
chemorefractory patients and multiply relapsed pa-
tients. Patient selection, with attention to optimal con-
trol of the HIV infection as well as appropriate choices
of antiretrovirals to minimize chances of myelosup-
pression or drug interactions, is also important. Early
posttransplant infections tend to be similar to the
HIV-negative setting, with bacterial infections pre-
dominating. Subsequently, OIs may be seen, and
need to be managed with an appropriate strategy of
prophylaxis for PCP, MAI, VZV, and surveillance
for CMV.Allogeneic SCT
Data on the role of allogeneic transplant in HIV-
infected patients is more limited. However, there is
a large experience in solid organ transplantation that
can be extrapolated to allogeneic SCT [12]. Experi-
ence in renal transplantation has demonstrated that
HIV-infected patients can tolerate chronic immuno-
suppression. However, attention should be paid to
the potential interaction between antiretrovirals and
immunosuppressants. Antiretrovirals that affect the
cytochrome p450 system are of most concern because
of the effects on drug levels of cyclosporine (CsA) and
tacrolimus. Based on our experience in autologous
transplant in HIV-positive patients, one can anticipate
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patients. However, in theHIV-negative allogeneic set-
ting, T cell recovery occurs initially with CD81 cells
[13]. Recovery of CD41 cells is longer, on the order
of 6 months. In HIV-positive patients it is unknown
if a similar pattern of recovery of cells will be seen.
The most similar group would be patients with non-
HIV-mediated immunodeficiency.When they achieve
partial chimerism postallograft, recovery of T cell
functions can be seen.
The largest series of allografted HIV-positive pa-
tients was from the EBMT. They reported on 30 pa-
tients transplanted between 1987 and 2003 [14]. The
eatm patients received a variety of conditioning regi-
mens and GVHD prophylaxis. The incidence of grade
II-IV acute GVHD (aGVHD) was 9%. The treatment
related mortality (TRM) was extremely high at 46%
100-day mortality. However, because many of these
patients were in the pre-HAART era, the deaths be-
cause of infection and HIV disease are not unexpected.
Of note, there was a marked difference in mortality in
patients transplanted after 1996, which heralded the
widespread use of HAART. Four of the 8 survived,
versus only 2 of 22 pre-HAART. One can postulate
that the mortality will continue to decline because of
factors such as the advent of RIC in conjunction with
better HIV therapy and infection prophylaxis.Future Directions of Transplantation in HIV-
Positive Patients
Many questions remain to be studied about the
role of transplantation in patients with underlying
HIV infection. For example, in the autologous setting
in HIV patients we know that CD4 count recovery will
occur by 1-year posttransplant [15]. Once patients are
back on HAART their viral loads will go down to low
levels within that first year as well. However, we do not
know what effect the transplant had on the HIV reser-
voirs in the body. For instance, are we depleting these
reservoirs with the intensive antilymphoid chemother-
apy, which may ultimately have positive long-term ef-
fects on the HIV infection? If we rescue patients with
HIV-negative allogeneic stem cells we may be able to
establish a newly competent immune system that can
prevent HIV progression. Alternately, strategies such
as donor-derived HIV-specific CTL infusions could
be used. In both the autologous and allogeneic setting,
the myeloablative therapy is also the ideal platform to
study strategies such as gene transfer to treat the HIV
infection. A protocol is ongoing at the City of Hope
that uses a multiplexed anti-HIV gene transfer strategy
to render autologous stem cells resistant to theHIV vi-
rus. Patients with HIV lymphoma then undergo mye-
loablative chemotherapy and are rescued with both
unmanipulated and genetically transduced cells. Two
patients have undergone successful transplantationwith this approach, and are being followed for evi-
dence of genetic marking.
Ultimately, optimal patient selection remains
crucial to transplant outcomes, especially in ‘‘at-risk’’
patients such as those with HIV-related immune
deficiency. Most trials have used standard organ func-
tion testing as eligibility criteria. However, further risk
stratification such as the use of the comorbidity index
may be of help especially as we expand our use of trans-
plant in these patients.ACKNOWLEDGMENTS
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